Method is presented for monitoring time-varying fluorescence. The method includes providing a measurement data set, transforming each Flr signal of each measurement data entry of the measurement data set to an agent intrinsic fluorescent (IF) signal, monitoring the agent IF signal for each measurement data entry within the measurement data set, whereby fluorescence emission of the agent is determined with reduced sensitivity to the time-varying optical properties of the medium.
Method is presented for monitoring time-varying fluorescence. The method includes providing a measurement data set, transforming each Flr signal of each measurement data entry of the measurement data set to an agent intrinsic fluorescent (IF) signal, monitoring the agent IF signal for each measurement data entry within the measurement data set, whereby fluorescence emission of the agent is determined with reduced sensitivity to the time-varying optical properties of the medium.
Method, system, and apparatus determines glomerular filtration rate (GFR) by obtaining a measurement data set. Furthermore, the disclosure includes obtaining a measurement data set comprising a plurality of measurement entries that are obtained before and after administration of an exogenous fluorescent agent; generating an intrinsic fluorescence (IF) signal representing a detected fluorescence intensity emitted by the exogenous fluorescent agent from within a diffuse reflecting medium; determining if the IF signal includes a portion of premature fluorescence data; identifying, upon determination of the portion of premature fluorescence data, an operable IF signal range by filtering the IF signal associated with premature fluorescence data; determining a GFR value in the patient based on a rate of change of the operable IF signal; providing the GFR value.
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
4.
INTRINSIC FLUORESCENCE GENERATION USING EXOGENOUS FLUORESCENCE AGENT
Method, system, and apparatus determines glomerular filtration rate (GFR) by obtaining a measurement data set. Furthermore, the disclosure includes obtaining a measurement data set comprising a plurality of measurement entries that are obtained before and after administration of an exogenous fluorescent agent; generating an intrinsic fluorescence (IF) signal representing a detected fluorescence intensity emitted by the exogenous fluorescent agent from within a diffuse reflecting medium; determining if the IF signal includes a portion of premature fluorescence data; identifying, upon determination of the portion of premature fluorescence data, an operable IF signal range by filtering the IF signal associated with premature fluorescence data; determining a GFR value in the patient based on a rate of change of the operable IF signal; providing the GFR value.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
diagnostic agents, namely, tracer agents for diagnostic imaging for use with medical monitoring equipment; tracer imaging agent for medical diagnostics, medical imaging, and monitoring of physiological function medical devices, namely, devices for detecting tracer agents and monitoring physiological function
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Diagnostic agents, namely, tracer agents for use with
medical monitoring equipment; tracer agent for medical
diagnostics, medical imaging, and monitoring of
physiological function.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Diagnostic agents, namely, tracer agents for use with medical monitoring equipment, for medical diagnostic use; diagnostic agents, namely, tracer agents for medical diagnostics; diagnostic agents, namely, tracer agents for use with medical imaging equipment, for medical diagnostic use; diagnostic agents, namely, tracer agents for monitoring of physiological function, for medical diagnostic use
10.
Method for non-invasive monitoring of fluorescent tracer agent with diffuse reflecting medium with time-varying optical properties
A method of assessment of renal function by monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a diffuse reflecting medium with time-varying optical properties is provided that includes using a renal monitoring system comprising at least one light source, at least one light detector, at least one optical filter, and at least one controller to provide a measurement data set comprising a plurality of measurement entries, each measurement data entry comprising at least two measurements obtained at one data acquisition time from a patient before and after administration of the fluorescent agent.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
12.
SYNTHESIS AND PURIFICATION OF SUBSTITUTED PYRAZINES
C07D 241/02 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles
C07D 241/10 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
C07D 241/14 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
diagnostic agents, namely, tracer agents for diagnostic imaging for use with medical monitoring equipment; tracer imaging agent for medical diagnostics, medical imaging, and monitoring of physiological function
14.
Method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and synthetic intermediate thereof
A method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and a synthetic intermediate thereof. The method comprises the step of preparing pyrimido[4,5-g]pteridine-2,4,7,9(1H,3H,6H,8H)-tetraone or a disalt (pteridine) thereof from 5-aminouracil or a single salt thereof.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
15.
COMPOSITIONS AND SYSTEMS FOR RENAL FUNCTION DETERMINATION
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
A method for determining a glomerular filtration rate (GFR) in a patient includes administering to said patient a compound of Formula I and transdermally measuring spectral energy emitted by the compound of Formula I over a measurement time window. The spectral energy is emitted by the compound of Formula I in response to electromagnetic radiation delivered to the compound of Formula I. The method also includes determining the GFR in said patient based on the measured spectral energy emitted by the compound of Formula I over the measurement time window by fitting an exponential function to the spectral energy as a function of time or a linear function to the log of the spectral energy as a function of time to calculate a rate constant associated with renal clearance over the measurement time window and directly related to the GFR normalized to a body size metric of the patient.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
The present invention relates to a method for determining an organ function in a subject, comprising the steps of: providing a first concentration-time curve obtained by transcutaneously measuring in a body fluid at a first position background fluorescence in at least one first time point and fluorescence of an indicator compound in at least a second, a third, a fourth, a fifth, and a sixth time point; providing a second concentration curve obtained by transcutaneously measuring in a body fluid at a second position background fluorescence in at least one seventh time point and fluorescence of an indicator compound in at least a eighth, a ninth, a tenth, an eleventh, and a twelfth time point; fitting the first and the second concentration curve into a kinetic model representing at least four diffusion compartments; and thereby determining an organ function in a subject. The invention further relates to a device for determining an organ function according to the method of the present invention, said device comprising a first sensor for transcutaneously measuring fluorescence of an indicator at a first position, a second sensor for transcutaneously measuring fluorescence of an indicator at a second position; and a data processing unit for fitting the values obtained by the sensors into a kinetic model of one of the preceding claims. The present invention also relates to a kit comprising a device of the present invention and an indicator compound, as well as to a computer or computer network comprising at least one processor, wherein the computer or computer network is adapted to perform the method according to the present invention.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A method of assessment of renal function by monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a diffuse reflecting medium with time-varying optical properties is provided that includes using a renal monitoring system comprising at least one light source, at least one light detector, at least one optical filter, and at least one controller to provide a measurement data set comprising a plurality of measurement entries, each measurement data entry comprising at least two measurements obtained at one data acquisition time from a patient before and after administration of the fluorescent agent.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
C07D 241/10 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease state, and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered. Establishing the baseline may include enterally administering a first dosage of a composition comprising a fluorescent tracer, measuring a first amount of the administered dose that can be found outside the gut over a period of time, and determining a baseline total percentage of the administered dose recovered. Measuring gut permeability may include enterally administering a second dosage of the composition, measuring a second amount of the administered dose, and determining a second total percentage of the administered dose recovered.
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
The present invention provides methods for the purification of the compound of Formula (I) from the precipitated reaction product comprising the compound of Formula (I), impurities, and/or residual or entrained solvents.
C07D 241/12 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
The present invention provides methods for the purification of the compound of Formula (I) from the precipitated reaction product comprising the compound of Formula (I), impurities, and/or residual or entrained solvents.
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
25.
PREPARATION OF SUBSTITUTED DIAMINOPYRAZINE DICARBOXYLIC ACIDS
C07D 241/12 - Composés hétérocycliques contenant des cycles diazine-1,4 ou diazine-1,4 hydrogéné non condensés avec d'autres cycles comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec uniquement des atomes d'hydrogène, des radicaux hydrocarbonés ou des radicaux hydrocarbonés substitués, liés directement aux atomes de carbone du cycle
The disclosure provides for methods for monitoring mucosal healing in a patient with a digestive disease, or for use in a pre-disease stat and includes intestinal as well as extra-intestinal disorders in which gut permeability is increased. The method may include establishing a baseline of the patient, treating the patient for the digestive disease or the pre-disease state, measuring gut permeability of the patient after treatment, and comparing a second total percentage of the administered dose recovered to the baseline total percentage of the administered dose recovered.
Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
The present disclosure relates to methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method comprises administering, subcutaneously or intramuscularly, a pyrazine compound of Formula I to a patient, wherein the administration produces a plasma concentration of the compound that is substantially similar to a plasma concentration produced by intravenous administration of an identical amount of the compound; and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which may be detected using one or more sensors. The rate in which the fluorescence decreases in the patient may be used to calculate the renal glomerular filtration rate in the patient.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
The present disclosure relates to methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method comprises administering, subcutaneously or intramuscularly, a pyrazine compound of Formula I to a patient, wherein the administration produces a plasma concentration of the compound that is substantially similar to a plasma concentration produced by intravenous administration of an identical amount of the compound; and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which may be detected using one or more sensors. The rate in which the fluorescence decreases in the patient may be used to calculate the renal glomerular filtration rate in the patient.
A method for preparing a 3,6-diaminopyrazine-2,5-dicarboxylic acid and a synthetic intermediate thereof. The method comprises the step of preparing pyrimido[4,5-g]pteridine-2,4,7,9 (1H,3H,6H,8H)-tetrone or a disalt (pteridine) thereof from 5-aminouracil or a single salt thereof.
C07D 475/02 - Composés hétérocycliques contenant des systèmes cycliques ptéridine avec un atome d'oxygène lié directement en position 4
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
31.
FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION
The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 formulas I and II may be characterized as electron withdrawing groups, white Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
The present invention relates to pyrazine derivatives such as those represented by Formulas I and II. X1 to X4 formulas I and II may be characterized as electron withdrawing groups, white Y1 to Y4 of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing organ (e.g., kidney) function. In a particular example, an effective amount of a pyrazine derivative that is capable of being renally cleared may be administered into a patient's body. The pyrazine derivative may capable of one or both absorbing and emanating spectral energy of at least about 400 nm (e.g., visible and/or infrared light). At least some of the derivative that is in the body may be exposed to spectral energy and, in turn, spectral energy may emanate from the derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to wirelessly communicatively couple the mobile computing device to a GI sensor (optionally by displaying instructions on a pairing screen), display a sensor placement screen that instructs the user to place the GI sensor on a body of a patient, prompts the user to administer a GI agent into the body of the patient; transmit a signal from the mobile computing device to the GI sensor to cause the GI sensor to initiate collection of light absorbance data for calculating GI function of the patient; receive light absorbance data from the GI sensor, and store the received light absorbance data.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
35.
SYSTEMS AND METHODS FOR HOME TRANSDERMAL ASSESSMENT OF GASTROINTESTINAL FUNCTION
Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to wirelessly communicatively couple the mobile computing device to a GI sensor (optionally by displaying instructions on a pairing screen), display a sensor placement screen that instructs the user to place the GI sensor on a body of a patient, prompts the user to administer a GI agent into the body of the patient; transmit a signal from the mobile computing device to the GI sensor to cause the GI sensor to initiate collection of light absorbance data for calculating GI function of the patient; receive light absorbance data from the GI sensor, and store the received light absorbance data.
A process for preparing pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, or a salt thereof, is provided. A process for the preparation of 3,6-diaminopyrazine-2,5-dicarboxylic acid, or a salt thereof, from pyrimido[4,5-g]pteridine-2,4,7,9-tetraol, or a salt thereof, is further provided. A process for preparing a substituted pteridine compound, or a salt thereof, is further provided. A process for the preparation of a N-substituted 3,6-diaminopyrazine-2,5-dicarboxylic acid from a substituted pteridine compound, or a salt thereof, is further provided.
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
Disclosed herein is a housing assembly configured to attach to a body surface of a patient and comprising at least one opening; a skin sensor movably disposed in the at least one opening of the housing assembly; and wherein the housing assembly is configured to move independently relative to the skin sensor when an external force is applied to the housing assembly.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/022 - Mesure de la pression dans le cœur ou dans les vaisseaux sanguins par application d'une pression pour fermer les vaisseaux sanguins, p. ex. contre la peauOphtalmodynamomètres
A method of assessment of renal function by monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a diffuse reflecting medium with time-varying optical properties is provided that includes using a renal monitoring system comprising at least one light source, at least one light detector, at least one optical filter, and at least one controller to provide a measurement data set comprising a plurality of measurement entries, each measurement data entry comprising at least two measurements obtained at one data acquisition time from a patient before and after administration of the fluorescent agent.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
ggg]pteridine-2,4,7,9-tetraol, or a salt thereof, is further provided. A process for preparing a substituted pteridine compound, or a salt thereof, is further provided. A process for the preparation of a N-substituted 3,6-diaminopyrazine-2,5-dicarboxylic acid from a substituted pteridine compound, or a salt thereof, is further provided.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
A sensor plaster (116) for the transcutaneous measurement of an organ function, more particularly of a kidney function, is proposed. The sensor plaster (116) comprises at least one flexible carrier element (134) having at least one adhesive surface (138) which can be stuck onto a body surface. Furthermore, the sensor plaster (116) comprises at least one radiation source, more particularly a light source (142), wherein the radiation source is designed to irradiate the body surface with at least one interrogation light (162). Furthermore, the sensor plaster (116) comprises at least one detector (146) designed to detect at least one response light (176) incident from the direction of the body surface.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 90/00 - Instruments, outillage ou accessoires spécialement adaptés à la chirurgie ou au diagnostic non couverts par l'un des groupes , p. ex. pour le traitement de la luxation ou pour la protection de bords de blessures
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
A sensor head is provided. In any of the various aspects of the invention, the sensor head has a housing enclosing at least two light sources configured to deliver light to a patient and comprising a blue LED first light source that delivers light at an excitatory wavelength and a green LED second light source, and at least one light detector configured to detect light at an emission wavelength from the patient. The sensor is useful for non-invasive monitoring of fluorescent tracers agents.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Diagnostic agents, namely, tracer agents for medical
diagnostic imaging purposes. Medical devices, namely, devices for detecting tracer agents
and monitoring physiological function.
51.
SYSTEMS AND METHODS FOR HOME TRANSDERMAL GFR MONITORING
Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to display a pairing screen that instructs a user to wirelessly communicatively couple the mobile computing device to a GFR sensor, display a sensor placement screen that instructs the user to place the GFR sensor on a body of a patient, display an injection screen that instructs the user to administer a GFR agent into the body of the patient; transmit a signal from the mobile computing device to the GFR sensor to cause the GFR sensor to initiate collection of light absorbance data for calculating a GFR of the patient; receive light absorbance data from the GFR sensor, and store the received light absorbance data.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
52.
SYSTEMS AND METHODS FOR HOME TRANSDERMAL GFR MONITORING
Disclosed herein is a non-transitory computer-readable media having computer-executable instructions thereon. When executed by the processor of a mobile computing device, the computer-executable instructions cause the processor to display a pairing screen that instructs a user to wirelessly communicatively couple the mobile computing device to a GFR sensor, display a sensor placement screen that instructs the user to place the GFR sensor on a body of a patient, display an injection screen that instructs the user to administer a GFR agent into the body of the patient; transmit a signal from the mobile computing device to the GFR sensor to cause the GFR sensor to initiate collection of light absorbance data for calculating a GFR of the patient; receive light absorbance data from the GFR sensor, and store the received light absorbance data.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Diagnostic agents, namely, tracer agents for medical photonic diagnostic imaging purposes
(2) Medical diagnostic devices, namely, photonic devices for detecting tracer agents and monitoring physiological function
Disclosed herein is a two-piece sensor assembly that includes an attachment collar configured to attach to a body surface of a patient and comprising at least one opening, and a skin sensor configured to seat into the at least one opening in the attachment collar. The skin sensor includes at least one radiation source configured to irradiate the body surface with at least one interrogation light, and at least one detector configured to detect at least one response light incident from the direction of the body surface.
Disclosed herein is a two-piece sensor assembly that includes an attachment collar configured to attach to a body surface of a patient and comprising at least one opening, and a skin sensor configured to seat into the at least one opening in the attachment collar. The skin sensor includes at least one radiation source configured to irradiate the body surface with at least one interrogation light, and at least one detector configured to detect at least one response light incident from the direction of the body surface.
Disclosed herein is a two-piece sensor assembly that includes an attachment collar configured to attach to a body surface of a patient and comprising at least one opening, and a skin sensor configured to seat into the at least one opening in the attachment collar. The skin sensor includes at least one radiation source configured to irradiate the body surface with at least one interrogation light, and at least one detector configured to detect at least one response light incident from the direction of the body surface.
C07D 241/28 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle dans lesquels lesdits atomes de carbone ont des liaisons doubles à des atomes d'oxygène, de soufre ou d'azote
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Fluorescent tracer agent for use with medical monitoring
equipment; fluorescent tracer agent for medical diagnostics,
medical imaging, and monitoring of physiological function in
animals.
58.
Uses of transdermal glomerular filtration rate measurement in continuous renal replacement therapy
Disclosed herein is a method for determining a dosing prescription for a medicament in a patient undergoing CRRT. The method generally includes administering to the bloodstream of the patient a fluorescent agent; administering to the patient at least one dose of the medicament; performing CRRT on the patient after administering the fluorescent agent to the patient; exposing the fluorescent agent to visible or infrared light; monitoring transcutaneously a change in the spectral energy from the fluorescent agent over a period of time; correlating a change in intensity of the spectral energy from the fluorescent agent to a clearance rate of the fluorescent agent from the bloodstream in the patient; calculating a clearance rate of the medicament in the patient; determining an amount of the medicament in the bloodstream of the patient as a function of time; and adjusting a dosing prescription of the medicament to the patient.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/145 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang
Disclosed herein is a method for determining a dosing prescription for a medicament in a patient undergoing CRRT. The method generally includes administering to the bloodstream of the patient a fluorescent agent; administering to the patient at least one dose of the medicament; performing CRRT on the patient after administering the fluorescent agent to the patient; exposing the fluorescent agent to visible or infrared light; monitoring transcutaneously a change in the spectral energy from the fluorescent agent over a period of time; correlating a change in intensity of the spectral energy from the fluorescent agent to a clearance rate of the fluorescent agent from the bloodstream in the patient; calculating a clearance rate of the medicament in the patient; determining an amount of the medicament in the bloodstream of the patient as a function of time; and adjusting a dosing prescription of the medicament to the patient.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
(1) Fluorescent tracer agent for use with medical monitoring equipment; fluorescent tracer agent for medical photonic diagnostics, medical photonic imaging, and monitoring of physiological function in animals.
62.
Compositions and methods for assessing eye vasculature
Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
em signal detected by the unfiltered light detector during illumination by emission-wavelength light. The method further includes identifying a post-agent administration portion of the measurement data set; and transforming each Flr signal to an IF signal representing a detected fluorescence intensity emitted solely by the fluorescent agent.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Diagnostic agents, namely, tracer agents for medical
diagnostic imaging purposes. Medical devices, namely, devices for detecting tracer agents
and monitoring physiological function.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Diagnostic agents, namely, tracer agents for medical photonic diagnostic imaging purposes
(2) Medical diagnostic devices, namely, photonic devices for detecting tracer agents and monitoring physiological function
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
diagnostic agents, namely, tracer agents for medical diagnostic imaging purposes medical devices, namely, devices for detecting tracer agents and monitoring physiological function
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
diagnostic agents, namely, tracer agents for medical diagnostic imaging purposes medical devices, namely, devices for detecting tracer agents and monitoring physiological function
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Fluorescent tracer agent for use with medical monitoring
equipment; fluorescent tracer agent for medical diagnostics,
medical imaging, and monitoring of physiological function in
the human body. Medical devices, namely, devices for detecting fluorescent
tracer agents in humans and monitoring physiological
function in the human body.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
Fluorescent tracer agent for use with medical monitoring
equipment; fluorescent tracer agent for medical diagnostics,
medical imaging, and monitoring of physiological function in
the human body. Medical devices, namely, devices for detecting fluorescent
tracer agents in humans and monitoring physiological
function in the human body.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
10 - Appareils et instruments médicaux
Produits et services
(1) Fluorescent tracer agent for use with medical monitoring equipment; fluorescent tracer agent for medical photonic diagnostics, medical photonic imaging, and monitoring of physiological function in the human body.
(2) Medical diagnostic devices, namely, photonic devices for detecting fluorescent tracer agents in humans and monitoring physiological function in the human body.
The present invention relates to a method for determining an organ function in a subject, comprising the steps of: providing a first concentration-time curve obtained by transcutaneously measuring in a body fluid at a first position background fluorescence in at least one first time point and fluorescence of an indicator compound in at least a second, a third, a fourth, a fifth, and a sixth time point; providing a second concentration curve obtained by transcutaneously measuring in a body fluid at a second position background fluorescence in at least one seventh time point and fluorescence of an indicator compound in at least a eighth, a ninth, a tenth, an eleventh, and a twelfth time point; fitting the first and the second concentration curve into a kinetic model representing at least four diffusion compartments; and thereby determining an organ function in a subject. The invention further relates to a device for determining an organ function according to the method of the present invention, said device comprising a first sensor for transcutaneously measuring fluorescence of an indicator at a first position, a second sensor for transcutaneously measuring fluorescence of an indicator at a second position; and a data processing unit for fitting the values obtained by the sensors into a kinetic model of one of the preceding claims. The present invention also relates to a kit comprising a device of the present invention and an indicator compound, as well as to a computer or computer network comprising at least one processor, wherein the computer or computer network is adapted to perform the method according to the present invention.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
76.
Tissue sealant compositions, vascular closure devices, and uses thereof
The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.
In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
The present invention provides tissue sealant compositions and vasculature closure devices useful for the optical detection of tissue seal and/or clot formation. Compositions and devices of the present invention comprise optical dyes which undergo an observable change as the compositions and/or devices are incorporated into a tissue seal and/or clot, for example a change in fluorescence quantum yield and/or a change in visual color including a change in emission and/or absorption wavelength. Tissue sealants and vasculature closure devices of the present invention are useful for visualizing seal and/or clot formation, for example, during or after surgical procedures, after catheter removal, etc. The present invention further provides methods for formation and optical detection of tissue seals or vasculature puncture closures as well as medical kits useful for the formation and optical detection of tissue seals or vasculature puncture closures.
In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below.
4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
Disclosed herein is a method for analyzing the concentration of a fluorescent compound in the plasma of a patient. The method includes collecting a sample of plasma from a patient, diluting the sample with a solvent and analyzing the diluted sample by HPLC. The sample does not need to be dried down during sample preparation nor is an internal standard required.
G01N 1/38 - Dilution, dispersion ou mélange des échantillons
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
G01N 30/14 - Préparation par élimination de certains composants
G01N 30/22 - Injection dans des systèmes liquides à haute pression
C07D 229/00 - Composés hétérocycliques contenant des cycles de moins de cinq chaînons contenant deux atomes d'azote comme uniques hétéro-atomes du cycle
82.
METHOD FOR PREPARING AND ANALYZING FLUORESCENT COMPOUNDS IN PLASMA
Disclosed herein is a method for analyzing the concentration of a fluorescent compound in the plasma of a patient. The method includes collecting a sample of plasma from a patient, diluting the sample with a solvent and analyzing the diluted sample by HPLC. The sample does not need to be dried down during sample preparation nor is an internal standard required.
Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula (I) to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula I to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
A61M 5/00 - Dispositifs pour faire pénétrer des agents dans le corps par introduction sous-cutanée, intravasculaire ou intramusculaireAccessoires à cet effet, p. ex. dispositifs de remplissage ou de nettoyage, appuis-bras
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C09B 57/00 - Autres colorants synthétiques de structure connue
A61P 13/12 - Médicaments pour le traitement des troubles du système urinaire des reins
C09K 11/06 - Substances luminescentes, p. ex. électroluminescentes, chimiluminescentes contenant des substances organiques luminescentes
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The method includes administering a pyrazine compound of Formula (I) to a patient and monitoring the rate in which the kidneys of the patient eliminate the pyrazine from the systemic circulation of the patient. The pyrazine compound fluoresces when exposed to electromagnetic radiation which is detected using one or more sensors. The rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
The present disclosure relates to systems and methods for determining the renal glomerular filtration rate or assessing the renal function in a patient in need thereof. The system includes a computing device, a power supply, one or more sensors, and at least one tracer agent that fluoresces when exposed to electromagnetic radiation. The electromagnetic radiation is detected using the sensors, and the rate in which the fluorescence decreases in the patient is used to calculate the renal glomerular filtration rate in the patient.
Compositions and methods for assessing gut function are disclosed. They are designed to provide accurate, rapid, point-of-care or in-community assessment of enteric dysfunction.
The present invention relates to pyrazine derivatives such as those represented by Formulas I and II below.
4 of the compounds of Formulas I and II may be characterized as electron donating groups. Pyrazine derivatives of the present invention may be utilized in assessing renal function. In particular, an effective amount of a pyrazine derivative of the invention may be administered into a body of a patient. The pyrazine derivative that is in the body may be exposed to visible and/or infrared light to cause spectral energy to emanate from the pyrazine derivative. This emanating spectral energy may be detected and utilized to determine renal function of the patient.
C07D 241/26 - Atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile avec des atomes d'azote liés directement aux atomes de carbone du cycle
In certain aspects, the invention relates to processes for using renally excretable optical agents to detect one or more tissues of the renal system of a surgical patient. In certain aspects, the invention relates to a kit including a biocompatible composition containing one or more optical agents and instructions for using the optical agent(s) in a process of the present invention.
Compositions and methods for assessing blood vessels and organs of the body are disclosed herein, specifically methods for assessing the vasculature of the eye.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
C07K 5/078 - Dipeptides le premier amino-acide étant hétérocyclique, p. ex. Pro, His, Trp
A61B 1/04 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p. ex. endoscopesDispositions pour l'éclairage dans ces instruments combinés avec des dispositifs photographiques ou de télévision
A method of monitoring a time-varying fluorescence emitted from a fluorescent agent from within a diffuse reflecting medium with time-varying optical properties is disclosed that includes providing at least two measurements obtained from a patient before and after administration of the fluorescent agent that includes an Firmcassignal detected adjacent to the medium by a filtered light detector during illumination of the medium by excitatory-wavelength light, and at least one DR signal selected from: a DRexmeas_ DRem, and DRem flltered signal. The method further includes identifying a post-equilibration portion of the measurement data set and transforming each F7rmeassignal within the post-equilibration portion of the measurement data set to an IFagent signal representing a detected fluorescence intensity emitted solely by the fluorescent agent from within the medium. The disclosed method includes removing the effects of leak-through of excitation-level light and removing the effects of autofluorescence from the Flrmeas signal.
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
G01J 1/42 - Photométrie, p. ex. posemètres photographiques en utilisant des détecteurs électriques de radiations
G01J 1/58 - Photométrie, p. ex. posemètres photographiques en utilisant une luminescence produite par la lumière
G01N 21/25 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
A method of monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a medium with time-varying optical properties is provided that includes providing a measurement data set that includes a plurality of measurement entries that include at least two measurements obtained from a patient before and after administration of the fluorescent agent. The measurements may include one or more of: a DR ex signal detected by an unfiltered light detector during illumination by excitatory-wavelength light from first region adjacent to the diffuse reflecting medium; a Flr signal detected by a filtered light detector during illumination by excitatory-wavelength light; and a DR em signal detected by the unfiltered light detector during illumination by emission-wavelength light. The method further includes identifying a post-agent administration portion of the measurement data set; and transforming each Flr signal to an IF signal representing a detected fluorescence intensity emitted solely by the fluorescent agent.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 21/62 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente
em signal detected by the unfiltered light detector during illumination by emission-wavelength light. The method further includes identifying a post-agent administration portion of the measurement data set; and transforming each Flr signal to an IF signal representing a detected fluorescence intensity emitted solely by the fluorescent agent.
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
A method of monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a medium with time-varying optical properties is provided that includes providing a measurement data set that includes a plurality of measurement entries that include at least two measurements obtained from a patient before and after administration of the fluorescent agent. The measurements may include one or more of: a DRex signal detected by an unfiltered light detector during illumination by excitatory-wavelength light from first region adjacent to the diffuse reflecting medium; a Flr signal detected by a filtered light detector during illumination by excitatory-wavelength light; and a DRem signal detected by the unfiltered light detector during illumination by emission-wavelength light. The method further includes identifying a post-agent administration portion of the measurement data set; and transforming each Flr signal to an IF signal representing a detected fluorescence intensity emitted solely by the fluorescent agent.
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
G01N 21/62 - Systèmes dans lesquels le matériau analysé est excité de façon à ce qu'il émette de la lumière ou qu'il produise un changement de la longueur d'onde de la lumière incidente
A method of monitoring a time-varying fluorescence emitted from a fluorescent agent from within a diffuse reflecting medium with time-varying optical properties is disclosed that includes providing at least two measurements obtained from a patient before and after administration of the fluorescent agent that includes an Flrmeas signal detected adjacent to the medium by a filtered light detector during illumination of the medium by excitatory-wavelength light, and at least one DR signal selected from: a DRexmeas DRem, and DRem,filtered signal. The method further includes identifying a post-equilibration portion of the measurement data set and transforming each Flrmeas signal within the post-equilibration portion of the measurement data set to an IFagent signal representing a detected fluorescence intensity emitted solely by the fluorescent agent from within the medium. The disclosed method includes removing the effects of leak-through of excitation-level light and removing the effects of autofluorescence from the Flrmeas signal.
G01N 21/25 - CouleurPropriétés spectrales, c.-à-d. comparaison de l'effet du matériau sur la lumière pour plusieurs longueurs d'ondes ou plusieurs bandes de longueurs d'ondes différentes
C40B 30/04 - Procédés de criblage des bibliothèques en mesurant l'aptitude spécifique à se lier à une molécule cible, p. ex. liaison anticorps-antigène, liaison récepteur-ligand
F21V 9/16 - Emploi de matériaux luminescents spécifiés comme écrans de lumière
G01J 1/42 - Photométrie, p. ex. posemètres photographiques en utilisant des détecteurs électriques de radiations
G01J 1/58 - Photométrie, p. ex. posemètres photographiques en utilisant une luminescence produite par la lumière
A method of monitoring a time-varying fluorescence signal emitted from a fluorescent agent from within a medium with time-varying optical properties is provided that includes providing a measurement data set that includes a plurality of measurement entries that include at least two measurements obtained from a patient before and after administration of the fluorescent agent. The measurements may include one or more of: a DR ex signal detected by an unfiltered light detector during illumination by excitatory-wavelength light from first region adjacent to the diffuse reflecting medium; a Flr signal detected by a filtered light detector during illumination by excitatory-wavelength light; and a DR en, signal detected by the unfiltered light detector during illumination by emission-wavelength light. The method further includes identifying a post-agent administration portion of the measurement data set; and transforming each Flr signal to an IF signal representing a detected fluorescence intensity emitted solely by the fluorescent agent.(see Fig.13)
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
A61B 5/1455 - Mesure des caractéristiques du sang in vivo, p. ex. de la concentration des gaz dans le sang ou de la valeur du pH du sang en utilisant des capteurs optiques, p. ex. des oxymètres à photométrie spectrale
